Showing 4671-4680 of 5771 results for "".
- Bionic Sight Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Retinitis Pigmentosahttps://modernod.com/news/bionic-sight-llc-doses-first-patient-in-a-phase-1-2-clinical-trial-of-a-new-investigational-treatment-for-blindness-caused-by-retinitis-pigmentosa/2477902/Bionic Sight announced that it has dosed the first patient in the company’s phase 1/2 clinical trial of BS01, an optogenetic gene therapy for patients with retinitis pigmentosa. This is an important step toward bringing BS01 forward as a treatment to enable patients with retinal degenerative dise
- Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Programhttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-medicinal-product-designation-from-the-european-commission-for-adx-2191-retinal-disease-program/2477898/Aldeyra Therapeutics announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. ADX-2191 is an investigational therapy in clinical development in the U.S. for the prevention of proliferative vitreoretinopathy (PVR),
- AstraZeneca to Supply Europe Up to 400 Million COVID-19 Vaccine Doseshttps://modernod.com/news/astrazeneca-to-supply-europe-up-to-400-million-covid-19-vaccine-doses/2479514/AstraZeneca announced that it has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA) to supply up to 400 million doses of the University of Oxford’s COVID-19 experimental vaccine, with deliveries starting by the end of this year. CEO Pascal Soriot remarked that ̶
- AORN Releases Survey Results Exploring ORs’ Return to Pre-COVID-19 Surgical Volumeshttps://modernod.com/news/aorn-releases-survey-results-exploring-ors-return-to-pre-covid-19-surgical-volumes/2479521/The Association of periOperative Registered Nurses (AORN) announced survey results of more than 1,000 surgical nurse leaders in the United States regarding how their facilities are managing the resumption of elective surgeries. Key Findings The top three spec
- Implandata Launches Eyemate IOP-Tracking Service for Remote Monitoring and Improved Glaucoma Carehttps://modernod.com/news/implandata-launches-eyemate-iop-tracking-service-for-remote-monitoring-and-improved-glaucoma-care/2477870/Implandata Ophthalmic Products announced the launch of its web-based Eyemate IOP-Tracking Service for remote monitoring and management of glaucoma. The Eyemate provides eye doctors with IOP measurements collected anytime under patients’ normal life conditions. “Remote IOP monitoring provid
- AbbVie Enters Deal to Develop Antibody Therapeutic for COVID-19https://modernod.com/news/abbvie-enters-deal-to-develop-antibody-therapeutic-for-covid-19/2477869/AbbVie entered into a collaboration with Harbour BioMed, Utrecht University, and Erasmus Medical Center to develop an antibody therapeutic to prevent and treat COVID-19, the parties announced Friday. The fully human, neutralising antibody 47D11, which targets the conserved domain of the spike pro
- BVI Launches CryoTreq for Treatment of Retinal Tears and Detachmentshttps://modernod.com/news/bvi-launches-cryotreq-for-treatment-of-retinal-tears-and-detachments/2477863/BVI announced the European launch of CryoTreq—a single-use, handheld cryosurgery device for ophthalmology. The device functions without external connections to equipment, gas tanks, or power and does not require any service or maintenance. CryoTreq enables a minimally invasive ab externo a
- SightGlass Vision Granted CE Mark for Eyeglasses That Slow Myopia Progression in Childrenhttps://modernod.com/news/sightglass-vision-granted-ce-mark-for-novel-eyeglasses-that-slow-myopia-progression-in-children/2477859/SightGlass Vision announced it has achieved CE Mark approval for its first product – novel eyeglasses designed to slow the progression of myopia in children. The approval allows the SightGlass Vision to commercialize its suite of Diffusion Optics Technology (DOT) products across the EU,
- Devlyn Optical Partnering with Eyenuk to Offer Diabetic Retinopathy Screeninghttps://modernod.com/news/devlyn-optical-partnering-with-eyenuk-to-offer-diabetic-retinopathy-screening/2477858/Eyenuk and Devlyn Optical, an optical retailer with over 1,000 stores in Mexico, Guatemala, El Salvador, and the US, announced that they will collaborate to pilot diabetic retinopathy (DR) screening services at Devlyn
- Re-vana Therapeutics Raises $3.25 Million in Pre-Series A Financinghttps://modernod.com/news/re-vana-therapeutics-raises-3-25-million-in-pre-series-a-financing/2477857/Re-Vana Therapeutics, a privately-held specialty therapeutic and drug delivery company developing sustained-release therapeutics for significant sight-threatening ocular diseases, announced that it has closed $3.25 mi